📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-30 20:19
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Subsidiary Knovea Inks US Commercial Deal for 2 Injectables in ~$288M Market
Symbiotec Pharmalab's wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive strategic commercialization agreement with an undisclosed leading global pharmaceutical company for two Dual Chamber Vial (DCV) injectable products in the United States. Knovea will handle development, regulatory filings, manufacturing, and supply, while the partner manages US distribution. The agreement includes milestone payments across development and regulatory stages, along with profit-sharing post-launch. The two target products address an estimated US addressable market of approximately $288 million, where currently only the innovator offers a DCV presentation.
Confidence: HIGH
What changedKnovea Pharmaceutical entered into a definitive strategic partnership with a global pharma company for exclusive US distribution of two DCV injectables.
Why it mattersValidates Symbiotec's complex injectables DCV platform and opens up high-margin US market access with upfront milestones and recurring profit shares.
Target US Market Size: ~US$288 millionNumber of Products: 2Milestone & Profit Share Details: not disclosedPartner Name: not disclosed
📅 Short termPositive sentiment driver due to high-value US market validation for its proprietary DCV platform, though financial impact depends on development milestone schedules.
📈 Long termSignificantly strengthens Symbiotec's complex injectables vertical and could drive margin expansion via profit-sharing upon commercialization in the US.
⚠ Risk flags
- Regulatory approval risks in the US for complex injectable formulations
- Partner identity and exact financial consideration terms kept confidential
- Commercialization timeline dependent on successful development cycles
Key Highlights
Exclusive US distribution agreement signed for 2 Dual Chamber Vial (DCV) injectable products
Target products address an estimated US market size of approximately US$288 million
Deal structured with development/regulatory milestone payments plus post-launch profit sharing
Knovea responsible for development, US regulatory filings, manufacturing, and commercial supply
👀 What to Watch
Track timelines for US regulatory submissions and milestone receipt, as well as approval timelines for the two DCV products in future quarterly disclosures.
Subsidiary Knovea Inks US Commercial Deal for 2 Injectables in ~$288M Market
Symbiotec Pharmalab's wholly owned subsidiary, Knovea Pharmaceutical, has signed a definitive strategic commercialization agreement with an undisclosed leading global pharmaceutical company for two Dual Chamber Vial (DCV) injectable products in the United States. Knovea will handle development, regulatory filings, manufacturing, and supply, while the partner manages US distribution. The agreement includes milestone payments across development and regulatory stages, along with profit-sharing post-launch. The two target products address an estimated US addressable market of approximately $288 million, where currently only the innovator offers a DCV presentation.
Confidence: HIGH
What changedKnovea Pharmaceutical entered into a definitive strategic partnership with a global pharma company for exclusive US distribution of two DCV injectables.
Why it mattersValidates Symbiotec's complex injectables DCV platform and opens up high-margin US market access with upfront milestones and recurring profit shares.
Target US Market Size: ~US$288 millionNumber of Products: 2Milestone & Profit Share Details: not disclosedPartner Name: not disclosed
📅 Short termPositive sentiment driver due to high-value US market validation for its proprietary DCV platform, though financial impact depends on development milestone schedules.
📈 Long termSignificantly strengthens Symbiotec's complex injectables vertical and could drive margin expansion via profit-sharing upon commercialization in the US.
⚠ Risk flags
- Regulatory approval risks in the US for complex injectable formulations
- Partner identity and exact financial consideration terms kept confidential
- Commercialization timeline dependent on successful development cycles
Key Highlights
Exclusive US distribution agreement signed for 2 Dual Chamber Vial (DCV) injectable products
Target products address an estimated US market size of approximately US$288 million
Deal structured with development/regulatory milestone payments plus post-launch profit sharing
Knovea responsible for development, US regulatory filings, manufacturing, and commercial supply
👀 What to Watch
Track timelines for US regulatory submissions and milestone receipt, as well as approval timelines for the two DCV products in future quarterly disclosures.
Symbiotec Receives US FDA EIR with VAI Status for Pithampur SEZ Facility
Symbiotec Pharmalab Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Pithampur (SEZ), Madhya Pradesh. The regulatory inspection was conducted between August 10, 2026, and August 14, 2026. The U.S. FDA classified the inspection status as Voluntary Action Indicated (VAI), indicating successful closure of the inspection without critical regulatory roadblocks. This resolution ensures continuity of regulatory compliance for U.S. market supplies from this site.
Confidence: HIGH
What changedThe U.S. FDA successfully concluded its review of the Pithampur facility by issuing an EIR with a VAI classification.
Why it mattersA VAI status effectively closes the inspection cycle without escalation into warning letters or import alerts, de-risking exports to the critical U.S. pharmaceutical market.
Inspection start date: August 10, 2026Inspection end date: August 14, 2026June 2026 Revenue: Rs 218.15 cr
📅 Short termPositive sentiment for the stock as regulatory overhang from the August 2026 inspection is formally cleared.
📈 Long termMaintains regulatory compliance standing with the U.S. FDA, enabling steady commercialization and new product launches for the U.S. market.
⚠ Risk flags
- VAI indicates minor observations were present that require ongoing voluntary compliance adherence
Key Highlights
Received Establishment Inspection Report (EIR) from the U.S. FDA on September 29, 2026
Facility inspected: Pithampur (SEZ), Madhya Pradesh, India
Inspection period: August 10, 2026 to August 14, 2026
Assigned Voluntary Action Indicated (VAI) classification, concluding the regulatory audit
👀 What to Watch
Track subsequent product approvals, ANDA filings, and U.S. export revenue growth originating from the Pithampur facility in upcoming quarterly filings.
Symbiotec Q1FY27 Revenue Rises 7% to ₹218.2 Cr; Consolidated PAT Drops 53% to ₹14.1 Cr
Symbiotec Pharmalab reported its first quarterly results as a listed entity for Q1FY27, with consolidated revenue rising 7.4% YoY to ₹218.2 crore from ₹203.2 crore. Consolidated EBITDA declined 22% YoY to ₹45.2 crore, and consolidated PAT dropped 52.8% to ₹14.1 crore, largely due to ₹35 crore in drag from pre-operating opex (₹23 crore) and depreciation (₹12 crore) on new businesses. Meanwhile, core API business operating revenue grew 6% YoY to ₹215.3 crore with steady EBITDA margins of ~30%. The company has planned a total gross capex of approx. ₹1,666 crore by end FY27, with revenue commercialization expected in the next 6-12 months.
Confidence: HIGH
What changedReported Q1FY27 results showing earnings drag from unmonetized capex, alongside operational progress in Dual Chamber Vial ANDA filings and CDMO contracts.
Why it mattersWhile core API remains steady at ~30% EBITDA margins, bottom-line performance will remain suppressed until ₹1,000+ crore of new investments begin generating revenue over the coming 6-12 months.
Consolidated Revenue (Q1FY27): ₹218.2 crConsolidated PAT (Q1FY27): ₹14.1 crAPI Revenue (Q1FY27): ₹215.3 crPre-operating Opex Drag: ₹23 crPre-operating Depreciation Drag: ₹12 crTotal Est. Gross Capex by FY27: approx. ₹1,666 cr
📅 Short termProfitability pressure from newly capitalized assets and pre-revenue opex may weigh on sentiment despite steady core API performance.
📈 Long termStructural transformation underway as 10-year take-or-pay biotech contracts and complex injectables commercialize over the next 1-2 years.
⚠ Risk flags
- Execution and ramp-up delays in new capex lines
- Pending EIR from USFDA for Pithampur facility audit (August 2026)
- Earnings drag persisting if commercialization takes longer than 6-12 months
Key Highlights
Consolidated revenue up 7.4% YoY to ₹218.2 cr, while consolidated PAT fell 52.8% YoY to ₹14.1 cr
Pre-operating drag of ₹23 cr opex and ₹12 cr depreciation impacted consolidated profitability
Core API operating revenue stood at ₹215.3 cr with EBITDA of ₹65.8 cr (~30% margin)
Total estimated gross capex of approx. ₹1,666 cr by end-FY27 (~₹1,000 cr invested in new ventures)
Net debt reduced from ~₹398 cr (as of June 30, 2026) to ~₹326 cr post-IPO proceeds on Sept 20, 2026
👀 What to Watch
Track the commercialization timeline of new business lines over the next 6-12 months and monitor USFDA EIR receipt for the Pithampur facility audit conducted in August 2026.
Symbiotec Q1FY27 PAT Drops 53% to ₹14.1 Cr Amid ₹1,000+ Cr Capex Drag on New Units
Symbiotec Pharmalab released its Q1FY27 investor presentation following its September 2026 listing at an IPO issue size of ₹1,757 crore (priced at ₹988 per share). Consolidated revenue grew 7% YoY to ₹218.2 crore, but net profit fell 53% YoY to ₹14.1 crore due to operational drag from pre-commercialization investments in new businesses. Operating expenses of ₹23.2 crore and depreciation of ₹11.6 crore from uncommissioned projects impacted reported margins. Over 60% of total capex (₹1,000+ crore out of ₹1,475 crore gross capex) is deployed in new ventures expected to start revenue generation over the next 6-12 months.
Confidence: HIGH
What changedSymbiotec shared its maiden quarterly performance presentation post-listing, outlining financial results and execution status of its ₹1,666 crore total planned capex.
Why it mattersDemonstrates that core API operations remain profitable (~31% EBITDA margin), while overall earnings are temporarily suppressed by pre-operative overheads of new growth divisions.
Consolidated Revenue Q1FY27: ₹218.2 crConsolidated PAT Q1FY27: ₹14.1 crCapex in New Projects: ₹1,000+ CrsGross Capex as of 30th Jun 2026: ₹1,475 CrsIPO Issue Size: ₹1,757 Cr
📅 Short termEarnings reaction may be tempered by the 53% YoY drop in net profit caused by overheads from non-revenue generating assets.
📈 Long termSignificant potential if commercial execution succeeds, as 61% of capex enters monetization phase over the next 6-12 months supported by multi-year take-or-pay agreements.
⚠ Risk flags
- Pre-operating drag: ₹34.8 crore total opex and depreciation impact from new businesses
- Regulatory approval timelines for upcoming ANDA and USFDA EIR awaiting at Pithampur plant
Key Highlights
Consolidated revenue up 7% YoY to ₹218.2 crore; reported PAT decreased 53% YoY to ₹14.1 crore
New business drag included ₹23.2 crore in opex and ₹11.6 crore in depreciation for assets not yet yielding revenue
Core API revenue grew 6% YoY to ₹215.3 crore with steady EBITDA margins of 31%
Total gross capex stood at ₹1,475 crore as of June 30, 2026, with an estimated ₹1,666 crore by end of FY27
First generic ANDA filed for Dual Chamber Vials (DCV) in the US market in September 2026
👀 What to Watch
Track the commercialization timeline of the ₹1,000+ crore capex in Complex Injectables and CDMO services over the next 6-12 months, along with USFDA EIR clearance for the Pithampur plant.
Symbiotec Pharmalab Posts Q1 FY27 Results; Reports Standalone Loss of ₹156.90M Amid Recent Listing
Symbiotec Pharmalab reported its unaudited financial results for the quarter ended June 30, 2026, marking its first post-IPO quarterly reporting following its September 1, 2026 stock exchange listing. For Q1 FY27, the company registered a standalone net loss of ₹156.90 million compared to a profit of ₹445.05 million in Q1 FY26. Total standalone expenses stood at ₹1,818.97 million against ₹1,663.29 million in the year-ago period. The company completed an IPO raising ₹1,500.00 million via fresh issue and ₹16,070.00 million through an offer for sale at an issue price of ₹988 per share.
Confidence: HIGH
What changedSymbiotec Pharmalab published its first post-listing quarterly financial report, turning from a net profit of ₹445.05 million in Q1 FY26 to a net loss of ₹156.90 million in Q1 FY27.
Why it mattersAs a newly listed entity, tracking revenue traction, margin compression causes, and the execution on objects from the fresh issue proceeds is critical for gauging earnings stability.
Standalone Net Profit / (Loss) Q1 FY27: Rs. (156.90) millionStandalone Net Profit Q1 FY26: Rs. 445.05 millionFresh Issue Size (IPO): Rs. 1,500.00 millionOffer For Sale Size (IPO): Rs. 16,070.00 millionIPO Issue Price: Rs. 988 per share
📅 Short termMarket sentiment may be muted following the quarter's net loss reported shortly after the company's debut on the bourses.
📈 Long termPerformance will hinge on the company's core API and intermediates business scale, margin recovery, and effective utilization of fresh IPO capital.
⚠ Risk flags
- Swing from profit to loss in the first reported quarter post-IPO
- Unaudited/unreviewed Q4 FY26 balancing figures used as comparative periods
Key Highlights
Standalone net loss stood at ₹156.90 million for Q1 FY27 compared to a net profit of ₹445.05 million in Q1 FY26
Basic and diluted EPS dropped to negative ₹2.73 and ₹2.71 respectively for the quarter ended June 30, 2026
Completed IPO of 17,786,442 equity shares at ₹988 per share, consisting of a ₹1,500.00 million fresh issue and ₹16,070.00 million OFS
Total standalone expenses reached ₹1,818.97 million for Q1 FY27 versus ₹1,663.29 million in Q1 FY26
👀 What to Watch
Track the deployment of ₹1,500 million fresh IPO proceeds as updates are provided in upcoming reporting periods, alongside operational turnaround in profitability.
Symbiotec Reports Q1 FY27 Results; Notes Post-Quarter IPO Listing at Rs 988/share
Symbiotec Pharmalab Limited released its financial results for the quarter ended June 30, 2026, marking its first quarterly reporting under SEBI LODR post-listing. Subsequent to the quarter-end, the company listed on NSE and BSE on September 1, 2026, following an IPO of 1,77,86,442 equity shares at Rs 988 per share, which included a fresh issue of Rs 1,500.00 million and an OFS of Rs 16,070.00 million. For comparison, FY26 consolidated revenue from operations stood at Rs 8,451.65 million with net profit of Rs 1,158.28 million. SRBC & CO LLP issued an unmodified limited review report on the consolidated results.
Confidence: HIGH
What changedCompany announced its first financial results as a newly listed entity following its September 1, 2026 public listing.
Why it mattersProvides public market transparency on operating performance and updates on capital raised from the IPO fresh issue.
IPO issue price: Rs 988 per shareIPO fresh issue size: Rs 1,500.00 millionIPO OFS size: Rs 16,070.00 millionFY26 Consolidated Revenue: Rs 8,451.65 millionFY26 Consolidated Net Profit: Rs 1,158.28 million
📅 Short termMarket participants will assess the baseline performance metrics of the newly listed API manufacturer as trading continues post-listing.
📈 Long termFuture trajectory will depend on deployment of fresh issue proceeds to expand core API and intermediates capacity.
⚠ Risk flags
- Results of 4 small subsidiaries (total revenue Rs 8.48 million) were management-certified and not reviewed by auditors
Key Highlights
Completed IPO of 1,77,86,442 shares at Rs 988 per share, listing on NSE/BSE on September 1, 2026
IPO fresh issue aggregated to Rs 1,500.00 million, while OFS aggregated to Rs 16,070.00 million
Consolidated FY26 full-year revenue stood at Rs 8,451.65 million and net profit at Rs 1,158.28 million
Statutory auditor SRBC & CO LLP issued an unmodified limited review report
👀 What to Watch
Track the deployment of the Rs 1,500 million fresh issue IPO proceeds and the detailed Q1 FY27 growth figures in upcoming quarterly disclosures.
